NCT06526247 Evaluating Interventions for Intimate Partner Violence Use in Washington State
| NCT ID | NCT06526247 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston University |
| Condition | Intimate Partner Violence |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-11-18 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2024-11-18 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intimate partner violence (IPV), specifically physical and psychological aggression toward an intimate partner, represents a public health crisis that affects millions of Americans each year. There currently exists very little evidence from randomized controlled trials for the effectiveness of abuser intervention programs designed to prevent and end perpetration of IPV in the general population. This is troubling considering that approximately half a million men and women are court-mandated to these programs each year. The investigators will conduct a randomized control trial (RCT) investigating the efficacy of the Strength at Home (SAH) intervention in reducing intimate partner violence (IPV). The overarching aim of this study is to test the efficacy of SAH with court-involved-partner-violent men through an RCT comparing those who receive SAH with those who receive other standard IPV interventions offered in the state of Washington (treatment as usual- TAU). The specific aims are: 1.1: Compare the frequency of physical and psychological IPV, the primary outcomes of interest, across conditions as reported by the male participants and their intimate partners across Time 1 (baseline) and four 3-month follow ups (Times 2-5). It is expected that greater reductions in IPV frequencies will be evidenced in SAH than TAU over the course of the year. 1.2: Compare symptoms of PTSD, alexithymia, and alcohol use problems across conditions and assessment time points as reported by the male participants. It is expected that greater reductions in these symptoms will be evidenced in SAH than TAU over the course of the year. 1.3: Compare treatment satisfaction across conditions as reported by the male participants across the four 3-month follow ups (Times 2-5). It is expected that treatment satisfaction will be higher in SAH than TAU.
Eligibility Criteria
Inclusion Criteria: Men: 1. Identify as a man 2. Provide consent for the research team to contact his intimate partner(s) for data collection purposes; 3. Court-referred for IPV intervention in Washington state Women: 1. Identify as a woman 2. Were or currently are an intimate partner involved in an incident of IPV with a court-referred participant Exclusion Criteria: 1. demonstrates active psychosis that may interfere with their ability to participate in group 2. expresses prominent suicidal or homicidal ideation that requires hospitalization 3. does not possess proficiency in spoken English 4. periods of incarceration after study enrollment
Contact & Investigator
Casey Taft, PhD
PRINCIPAL INVESTIGATOR
BU School of Medicine and National Center for PTSD
Frequently Asked Questions
Who can join the NCT06526247 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intimate Partner Violence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06526247 currently recruiting?
Yes, NCT06526247 is actively recruiting participants. Contact the research team at taft@bu.edu for enrollment information.
Where is the NCT06526247 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06526247 clinical trial?
NCT06526247 is sponsored by Boston University. The principal investigator is Casey Taft, PhD at BU School of Medicine and National Center for PTSD. The trial plans to enroll 800 participants.